Ultra-low doses could bring costly cancer treatments to more patients in poorer countries

AI justification

Low-dose immunotherapy trial reduces costs and expands access to life-saving cancer treatment globally. | The trial represents a significant ethical advance by reducing financial barriers to life-saving cancer treatment, directly supporting SDG 3 (Good Health and Well-being) and UDHR Article 25 (right to medical care). The approach may mitigate global health disparities by making high-cost immunotherapies accessible in resource-limited settings, with no identified negative ethical aspects.